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Abstract
Background: Previous studies indicate that successful resolution of Lyme neuroborreliosis (NB) is associated with a
strong T helper (Th) 1-type cytokine response in the cerebrospinal fluid (CSF) followed by a down-regulating Th2
response, whereas the role of the recently discovered Th17 cytokine response is unknown.
Methods: To investigate the relative contribution of different Th associated cytokine/chemokine responses, we
used a multiple bead array to measure the levels of CXCL10 (Th1 marker), CCL22 (Th2 marker), IL-17 (Th17 marker)
and CXCL8 (general inflammation marker), in serum and in CSF from untreated patients with confirmed NB (n =
133), and non-NB patients (n = 96), and related the findings to clinical data. Samples from patients with possible
early NB (n = 15) and possible late NB (n = 19) were also analysed, as well as samples from an additional control
group with orthopaedic patients (n = 17), where CSF was obtained at spinal anaesthesia.
Results: The most prominent differences across groups were found in the CSF. IL-17 was elevated in CSF in 49%
of the patients with confirmed NB, but was not detectable in the other groups. Patients with confirmed NB and
possible early NB had significantly higher CSF levels of CXCL10, CCL22 and CXCL8 compared to both the non-NB
group and the control group (p < 0.0001 for all comparisons). Patients in the early NB group, showing a short
duration of symptoms, had lower CCL22 levels in CSF than did the confirmed NB group (p < 0.0001). Furthermore,
patients within the confirmed NB group showing a duration of symptoms <2 weeks, tended to have lower CCL22
levels in CSF than did those with longer symptom duration (p = 0.023). Cytokine/chemokine levels were not
correlated with clinical parameters or to levels of anti-Borrelia-antibodies.
Conclusion: Our results support the notion that early NB is dominated by a Th1-type response, eventually
accompanied by a Th2 response. Interestingly, IL-17 was increased exclusively in CSF from patients with confirmed
NB, suggesting a hitherto unknown role for Th17 in NB. However, for conclusive evidence, future prospective
studies are needed.
Background
Neuroborreliosis (NB) is the most common manifesta-
tion of disseminated borreliosis in Europe [1,2]. Most
patients recover after antibiotic treatment, while some
experience persisting symptoms despite adequate ther-
apy [3-8]. The pathogenic mechanisms behind the vari-
able outcome are not fully understood. Previous studies
have indicated that a good prognosis in NB seems to be
associated with a strong T helper (Th) 1-type immune
response in the cerebrospinal fluid (CSF) early in the
infection [9-15], followed by a Th2-type response, cap-
able of suppressing the Th1-type inflammation. If this
switching is delayed, there is a risk of tissue damage and
persisting symptoms [16-19].
The Th1/Th2 concept has recently been extended to
include a population called Th17, based on their secre-
tion of interleukin (IL)-17 [20]. Th17 cells are thought
to play a key role in the induction and development of
tissue injury in some autoimmune diseases, although so
far mainly shown in experimental models [21,22].
Recent studies have also demonstrated induction of IL-
17 preferentially in infections with extra-cellular bacteria
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and fungi [23]. It has been suggested that Th17 cells and
their associated cytokines are involved in the pathogen-
esis of Lyme arthritis [24-26], whereas data on Th17
involvement in NB is lacking.
Chemokines are small chemotactic cytokines that are
induced during an immune response to promote migra-
tion of immune cells to the site of infection [27]. Che-
mokines have a crucial role in establishing the Th1/Th2
balance and they are used as markers for Th1/Th2
immunity. The chemokine CXCL10 (IFN-g inducible
protein 10, IP-10) is secreted by several cell types, e.g.
monocytes, endothelial cells and fibroblasts [28] in
response to IFN-g, and plays an important role in
attracting T cells into sites of Th1-type inflammation
[29]. Previous studies have indicated the presence of
CXCL10 in CSF from NB patients [30] as well as in skin
samples from patients with dermatoborreliosis [31]. The
Th2-associated chemokine CCL22 (macrophage-derived
chemokine, MDC) is secreted by dendritic cells and
macrophages [32], and is a chemoattractant for mono-
cytes, immature dendritic cells and natural killer cells
[33]. CXCL8 (IL-8) is secreted by several cell types, e.g.
macrophages, dendritic cells and endothelial cells
[34,35]. Its primary function is to recruit neutrophil
granulocytes early in the inflammation process [36], and
CXCL8 can therefore be regarded as a general and early
marker of inflammation. Furthermore, CXCL8 is prob-
ably the most important neutrophil-attracting factor
induced by IL-17 [37].
The aim of this study was to assess Th associated
cytokine/chemokine profiles in serum and in CSF in NB
patients in the framework of a large retrospective study.
The relative contribution of Th1-, Th2-, and Th17-like
responses were estimated by the levels of CXCL10,
CCL22 and IL-17A (here referred to as IL-17), respec-
tively. CXCL8 was analyzed as a general marker of
inflammation. In addition, we also wanted to relate the
cytokine/chemokine levels to age, sex, clinical presenta-
tion and course of the disease.
Methods
Patients
Serum and CSF samples of 263 patients were investi-
gated for suspected NB during 2003 through 2005 at
the hospitals of Kalmar (n = 165) and Jönköping (n =
98). The domiciles of the patients were distributed all
over the Counties of Kalmar and Jönköping, respec-
tively. None of the patients had, in conjunction with the
current study, received antibiotic treatment for NB
prior to the lumbar puncture (LP). Elevated anti-Borre-
lia antibody index (AI) or increased levels of Borrelia-
specific IgG or IgM antibodies in CSF were found in
152 patients, whereas 111 patients had no detectable
Borrelia-specific antibodies in CSF. In the entire study
group (n = 263), there were 155 men (59%) and 108
women (41%). The median age in the whole group was
41 years, range 2-87 years. There were 95 (36%) patients
aged 15 years or less, and 168 (64%) patients were over
15 years of age. The patients were divided into four
groups based on the CSF findings (Table 1). Patients in
group 1 had both detectable Borrelia-specific antibodies
in CSF and pleocytosis. Group 2 had Borrelia-specific
antibodies in CSF, but no pleocytosis. Group 3 con-
sisted of 15 children with symptoms strongly indicative
of NB, i.e. subacute meningitis and/or facial palsy. They
had pleocytosis but no detectable Borrelia-specific anti-
bodies in CSF. Group 4 consisted of patients without
intrathecal anti-Borrelia antibodies and no pleocytosis,
thereby constituting a non-NB group. They had been
investigated for symptoms suggestive of NB, such as
facial palsy, headache, muscle and joint pain, vertigo or
fatigue. In addition to these four groups we used a con-
trol group (group 5) where CSF was not obtained due
to suspicion of NB; 17 patients undergoing elective
orthopaedic surgery, where CSF was collected prior to
spinal anaesthesia. The reference material was collected
at the University Hospital of Linköping from patients
that had not experienced NB and they were negative for
anti-Borrelia antibodies in serum and in CSF. Further
characteristics of the patient groups are presented in
Table 1.
Serum and CSF samples
The Clinical Laboratory of Microbiology (CLM) in Kal-
mar used an ELISA kit measuring intrathecal production
of Borrelia-specific antibodies, i.e. AI, (IDEIA Lyme
Neuroborreliosis, K6028, Dako Cytomation, UK). Results
were interpreted as negative or positive according to the
manufacturer’s instructions. Serum samples from
patients in Kalmar County were investigated with
Immunetics Quick ELISA Borrelia C6 Assay kit, Immu-
netics, Cambridge, MA, USA.
At the CLM in Jönköping the Lyme Borreliosis ELISA
kit 2nd Generation (Dako Cytomation, A/S, Glostrup,
Denmark) was used for measuring Borrelia-specific anti-
bodies in serum and in CSF. Results were interpreted as
positive or negative according to a cut-off adjusted to a
local sample collection used when validating the
method.
The control samples (group 5) were analysed for Bor-
relia-specific antibodies by ELISA kit measuring serum
and intrathecal production of antibodies (IDEIA Lyme
Neuroborreliosis, K6028, Dako Cytomation, UK).
All samples had been stored at -20°C and thawed once
before the current analyses. The cytokine/chemokine
and albumin analyses were performed in 2009 using
Luminex technology (see below) and rate nephelometry
(Beckman Coulter Immage 800), respectively.
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Cytokine/chemokine measurements
Concentrations were measured by Luminex multiple
bead technology (Milliplex Human Cytokine/Chemokine
Kit, Millipore Corporation) according to the instructions
provided by the manufacturer. The lower detection lim-
its were as follows; CXCL8: 1.6 pg/mL, IL-17: 1.6 pg/
mL, CXCL10: 16 pg/mL, CCL22: 80 pg/mL in serum, 20
pg/mL in CSF. Values under the detection limit were
given half the value of the lowest point of the standard
curve. The inter-assay coefficient of variation (CV) was
9.3-11.6%, and the intra-assay CV was 4.5-7.1% accord-
ing to the manufacturer. In the following, CXCL8,
CXCL10 and CCL22 are collectively referred to as che-
mokines; IL-17 is referred to as cytokine, whereas all
(CXCL8, CXCL10, CCL22 and IL-17) are referred to as
cytokine/chemokines.
Data handling and statistics
Statistical analyses were performed using SPSS for Win-
dows, version 15.0. Since most of the variables had
skewed distributions, non-parametric tests were used.
Kruskal-Wallis ANOVA was performed to compare
multiple study groups, and Mann-Whitney U test was
applied as a post-hoc test. For ordered categorical vari-
ables, the Chi2 test was used. Correlations between para-
meters were calculated using Spearman correlation
analysis (rho values are given). P-values < 0.01 were
considered to be significant, this p-value was chosen to
avoid mass-significance problems. By analogy to the
IgG-index used for calculations of intrathecal IgG pro-
duction [38], we calculated a “chemokine intrathecal
production index” using the formula (CSF-chemokine/S-
chemokine)/(CSF-albumin/S-albumin). The CCL22
Table 1 Characteristics of the different study groups.
Group 1
Confirmed NB
n = 133
Group 2
Possible late NB
n = 19
Group 3
Possible early NB
n = 15
Group 4
Non-NB
n = 96
Group 5
Control patients
n = 17
Borrelia-specific AI or
Borrelia-specific anti-
bodies in CSF
+ + - - -
CSF pleocytosis + - + - -
CSF-albumin
S-albumin median, (range)
16***
(3.4-76)
5.5
(2.4-21)
3.5
(0-12)
4.3
(0-22)
n.d.
Borrelia-specific IgG/IgM
antibodies detected in
serum; n, (%)
115***
(87)
15*
(79)
15***
(100)
42
(44)
0***
(0)
Men
n, (%)
80
(60)
14
(74)
9
(60)
52
(54)
9
(53)
Women
n, (%)
53
(40)
5
(26)
6
(40)
44
(46)
8
(47)
Median age
years, (range)
35**
(3-87)
52
(18-76)
7***
(2-13)
44
(2-83)
66*
(50-72)
Median duration of
symptoms before LP;
weeks, (range)
2.4
(0-32)
4.0
(0.1-77)
0.7
(0.1-4.0)
3.5
(0-730)
-
Head/neck pain
n, (%)
77
(58)
11
(58)
11
(73)
43
(45)
-
Cranial nerve palsy
n, (%)
70
(53)
4
(21)
11
(73)
13
(14)
-
Radiculitis
n, (%)
53
(40)
7
(37)
0
(0)
3
(3)
-
Other symptom
n, (%)
9
(7)
2
(11)
0
(0)
39
(41)
-
NB: neuroborreliosis.
n: number of patients.
AI: antibody index.
CSF:cerebrospinal fluid.
Pleocytosis:>5 mononuclear cells/μL CSF.
S: serum.
LP: lumbar puncture.
n.d: not done.
Patients could have one or more of the symptoms head/neck pain, cranial nerve palsy and radiculitis. Patients with none of the above symptoms were classified
as “other symptom” (e.g. vertigo, muscle and joint pain, parestesias, fatigue, dementia or concentration difficulties).
* significant differences compared to the non-NB group (group 4). * p < 0.01, **p < 0.001, ***p < 0.0001.
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index was multiplied by 100 due to the much higher
concentration in serum. IL-17 was not detectable in
CSF in three of the four patient groups, and thus no
data are given for the IL-17 intrathecal production
index. Albumin values were not available in all samples
from the control group (group 5).
Ethics
The study was approved by the Regional Ethical Review
Board in Linköping, Sweden.
Results
There were no differences in cytokine/chemokine levels
in serum or in CSF between men and women. When
comparing the patients under 15 years of age to patients
over 15 in the entire study population (groups 1-5), the
children had significantly higher CSF levels of CXCL8
(p < 0.0001), CXCL10 (p < 0.0001), CCL22 (p = 0.0001)
and IL-17 (p = 0.001). In serum, there were no differ-
ences in cytokine/chemokine levels between younger or
older patients, except for CCL22 that was higher in the
patients under 15 years of age (p < 0.0001).
The cytokine/chemokine data from the aspect of the
different study groups are presented in Figure 1. In
serum, there were few significant differences across
groups; the CXCL8 levels were decreased in group 3,
children with possible early NB (Figure 1a), whereas the
CXCL10 levels were increased in group 1, confirmed
NB and in group 5, the control group (Figure 1e). There
were no significant differences across groups regarding
IL-17 or CCL22 levels in serum.
In contrast to serum, CSF showed several significant
differences across the groups. Groups 1 and 3, i.e. con-
firmed NB and possible early NB, showed increased
levels of CXCL8 (Figure 1b) and CXCL10 (Figure 1f) as
compared to the other groups. For CCL22, the highest
levels were found in group 1, but CCL22 was also ele-
vated in group 3. Thus, regarding the kinetics of CCL22,
moderate levels of CCL22 were associated with short
symptom duration since group 3, with the shortest
symptom duration (p < 0.0001 when compared to group
1), showed lower CCL22 levels than group 1. In addi-
tion, patients within the confirmed NB group showing a
duration of symptoms <2 weeks, also tended to have
lower CCL22 CSF levels than did those with a longer
symptom duration (p = 0.023). Notably, IL-17 levels
were significantly higher in group 1, confirmed NB,
while it was not detectable in CSF of the other groups
(Figure 1d).
All the cytokine/chemokine levels in CSF correlated
with CSF pleocytosis when looking at the entire study
population, i.e. CXCL8: rho = 0.71, IL-17: rho = 0.54,
CXCL10: rho = 0.71, CCL22: rho = 0.83 (all p values
<0.0001, data not shown in figures). Furthermore,
cytokine/chemokine levels in CSF did not correlate with
the corresponding serum levels. The chemokine
intrathecal production indices for CXCL8, CXCL10 and
CCL22 were increased in groups 1 and 3 (Table 2), i.e.
confirmed NB and possible early NB.
Group 1, the confirmed NB group, showed signifi-
cantly higher CSF levels of all cytokine/chemokines
compared with groups 4, the non-NB group, and 5, the
control group (Figure 1). However, regarding clinical
parameters, there were no correlations within group 1
between cytokine/chemokine levels in CSF and either i)
age, ii) duration of symptoms prior to diagnosis, iii)
degree of pleocytosis in CSF, iv) intrathecal Borrelia-
specific antibodies, or v) duration of symptoms after
treatment (data not shown). Group 1 also showed
increased CSF levels of IL-17, being detected (i.e. >0.80
pg/mL) in 65 patients (49%), whereas IL-17 was not
detected in CSF of the other groups. However, there
were no significant differences between patients with
elevated IL-17 levels in CSF and the remaining group 1
patients regarding age, sex, duration of symptoms prior
to diagnosis or duration of symptoms after treatment.
Patients with elevated IL-17 in CSF had more pro-
nounced pleocytosis (p = 0.004) compared to the
patients in group 1 with undetectable levels of IL-17 in
CSF. There was no correlation within group 1 between
serum and CSF levels of IL-17 (rho = 0.09, p = 0.316),
or between the CSF-albumin/S-albumin ratio and IL-17
in CSF; (rho = 0.18, p = 0.045). Further, there was no
significant difference in CSF-albumin/S-albumin ratio
when comparing patients with elevated IL-17 in CSF to
those with low levels (p = 0.172) (Table 3). There were
no differences in clinical presentation between patients
with high or low CSF-IL-17, except for fatigue, being
more common in the group with high IL-17 levels
(Table 3).
Group 2, possible late NB, did not differ from the
non-NB group or the control group in their serum or
CSF levels regarding cytokine/chemokine levels or
intrathecal indices, except for higher serum levels of
CXCL10 in the control group (Figure 1e).
Since group 3 only consisted of children, we also
made comparisons between group 3 and the children in
groups 1 and 4, respectively (there were no children in
groups 2 and 5). The same differences between the
groups were obtained as when analysing the entire study
population (Table 4 and Figure 2).
Discussion
In this study we aimed at elucidating the balance of
cytokine/chemokines related to different Th cell popula-
tions including the recently described Th17 population.
For this purpose, a large material of collected serum and
CSF samples from patients with clinically suspected NB
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Figure 1 Cytokine/chemokine levels (pg/mL) in serum and in cerebrospinal fluid (CSF). Group 1: Confirmed neuroborreliosis (NB), patients
with elevated Borrelia-specific antibody index or Borrelia-specific antibodies in CSF and pleocytosis. Group 2: Possible late NB, patients with
elevated Borrelia-specific antibody index or Borrelia-specific antibodies in CSF but no pleocytosis. Group 3: Possible early NB, children with CSF
pleocytosis but no detectable Borrelia-specific antibodies in CSF. Group 4: Non-NB, patients without pleocytosis and no detectable Borrelia-
specific antibodies in CSF. Group 5: Control group, CSF was obtained at spinal anaesthesia from patients undergoing elective orthopaedic
surgery. Bars represent the median cytokine/chemokine level in each group.
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was used. The age and sex distribution were in accor-
dance with a previous study from the areas around Kal-
mar and Jönköping [1], supporting that the study
population is representative for NB patients. The
patients were stratified according to the primary findings
in the CSF. One large group (group 1) was regarded as
“confirmed NB” since these patients showed both CSF
pleocytosis and presence of intrathecal anti-Borrelia
antibodies [39]. The patients in group 2 had Borrelia-
specific antibodies in CSF, but no pleocytosis. They had
slightly longer duration of symptoms prior to diagnosis
compared to group 1, so in their case it is possible that
a previous pleocytosis had resolved by the time of the
LP, probably reflecting the natural course of NB in most
cases, even without treatment. Taking this into consid-
eration, group 2 could be regarded as patients with
“possible late NB”, although a number of cases could
well have been “status post” NB, and thus, we could not
draw any firm conclusions from this group. The patients
in group 3 were all children showing CSF pleocytosis
but no detectable Borrelia-specific antibodies in CSF.
They had a significantly shorter duration of symptoms
prior to the LP compared to group 1. Their clinical
symptoms were strongly indicative of NB; in all cases
subacute meningitis and/or facial palsy, a symptom that
in Scandinavia is commonly caused by Borrelia in pae-
diatric patients [40,41]. These patients were therefore
regarded as “possible early NB”. In further support of
this notion, we previously demonstrated that a similar
group of children with “possible NB” revealed Borrelia-
specific T-cell responses to the same extent as did chil-
dren with “confirmed NB” [42]. Another large group
(group 4, the non-NB group) could be regarded as a
kind of control group, since these patients had no signs
of CNS inflammation and no intrathecal Borrelia-speci-
fic antibodies. Group 4 consisted of patients investigated
for symptoms suggestive of NB, but without serologic
findings of current NB. A significantly larger proportion
of the patients in groups 1, 2 and 3 had detectable Bor-
relia-specific antibodies in serum compared to the
patients in group 4. However, the presence or absence
of anti-Borrelia antibodies in serum should be inter-
preted with caution, since the study is carried out in a
highly endemic area where patients could have been
exposed to Borrelia previously. Further, NB patients
may develop anti-Borrelia antibodies in CSF before the
antibodies are detectable in serum [43]. Group 5 con-
sisted of patients without a medical history of NB and
no current symptoms suggestive of NB. They did not
have CSF pleocytosis or detectable Borrelia-specific anti-
bodies in serum or in CSF, and were therefore included
as an additional and independent control group.
The most prominent differences across groups were
found in CSF. CXCL8 and CXCL10 were significantly
elevated in group 1 (confirmed NB) and in group 3
(possible early NB). CCL22 in CSF was particularly ele-
vated in group 1, and moderately elevated in group 3.
Here, the time aspect is probably of importance for the
chemokine profile. Early in the inflammation process, a
Th1-type immune response dominates (as in group 3,
possible early NB), but is then counter-balanced by a
Th2 response (as in group 1, confirmed NB). This pat-
tern is also found within group 1, i.e. patients with dura-
tion of symptoms <2 weeks also tended to have lower
CCL22 CSF levels than those with longer symptom
duration. This scenario corroborates previous observa-
tions and is in line with the hypothesis that Th2 con-
trols the primary Th1 response, the latter being crucial
in bacteria elimination but also potentially involved in
tissue damage [12-19].
Remarkably, half of the patients in group 1 had ele-
vated levels of IL-17 in CSF, whereas IL-17 was not
Table 2 CSF-albumin/S-albumin ratios and chemokine intrathecal production indices for the different patient groups¤.
Group 1
Confirmed NB
n = 133
Group 2
Possible late NB
n = 19
Group 3
Possible early NB
n = 15
Group 4
Non-NB
n = 96
CXCL8 index
median, (range)
0.23*
(0.01-2.3)
0.11
(0.01-0.5)
4.56***
(0.19-8.63)
0.16
(0-7.40)
CXCL10 index
median, (range)
3.13***
(0-76.7)
0.42
(0.02-1.08)
14.4***
(5.21-96.4)
0.59
(0-10.9)
CCL22 index
median, (range)
0.30***
(0-7.00)
0.07
(0-0.20)
0.20***
(0-2.00)
0.10
(0-7.00)
Chemokine index: (CSF-chemokine/S-chemokine)/(CSF-albumin/S-albumin).
NB: neuroborreliosis.
n: number of patients.
CSF: cerebrospinal fluid.
S: serum.
¤: Indices could not be calculated for group 5, since CSF-albumin/S-albumin ratios were not available for all.
The CCL22 index was multiplied by 100 due to much higher concentrations in serum.
The IL-17 index was not calculated since IL-17 was not detectable in CSF in groups 2, 3 and 4.
* significant differences compared to the non-NB group (group 4). * p < 0.01, ** p < 0.001, *** p < 0.0001.
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detectable in any of the other patient groups. The role
of the increase in IL-17 is still puzzling since there were
no significant differences between those with high levels
of IL-17 in CSF and those with low levels regarding sex,
age, duration of symptoms prior to diagnosis, or dura-
tion of symptoms after treatment. The significant find-
ings distinguishing patients with high levels of CSF-IL-
17 from those with low levels, were a more pronounced
pleocytosis, slightly more elevated CXCL10 in CSF and
a higher frequency of fatigue. These findings are hard to
interpret and need to be confirmed. The association
with pleocytosis suggests IL-17 to be associated with
ongoing inflammation, although the absence of IL-17 in
children with pleocytosis but no anti-Borrelia-antibodies
in CSF (group 3) is then puzzling. However, it could be
speculated that children show defective or delayed Th17
responses. The presence of IL-17 in CSF of NB patients
has only recently been reported in another cohort of NB
patients on the Islands of Åland [44]. Since IL-17 has
proven important in the context of extra-cellular bac-
teria, and in the induction of immune-mediated tissue
injury [45], further studies on IL-17 and its role in the
pathogenesis and clinical out-come of NB are required.
CXCL8 is one important effector mechanism asso-
ciated with IL-17, which is in line with the high CXCL8
levels in group 1. However, also the patients in group 3
(possible early NB) showed high levels of CXCL8 in
CSF, but no detectable IL-17, which suggests that
CXCL8 might be induced by other pathways indepen-
dent of IL-17.
We found several evidence supporting an intrathecal
origin of the induced cytokine/chemokines; no correla-
tions between serum and CSF levels, the levels being of
the same magnitude (or higher) in CSF compared to
serum for CXCL8, CXCL10 and IL-17, and increased
chemokine intrathecal production indices for CXCL8,
CXCL10 and CCL22 in groups 1 and 3. For IL-17, an
intrathecal production index could not be reliably calcu-
lated due to the absence of IL-17 in CSF of several
groups. Yet, it seems that IL-17 is produced intrathecally
Table 4 Characteristics of the children under 15 years of
age¤
Group 1
Confirmed
NB
n = 59
Group 3
Possible early
NB
n = 15
Group
4
Non-NB
n = 21
Borrelia-specific AI or
Borrelia-specific anti-
bodies in CSF
+ - -
CSF pleocytosis + + -
CSF-albumin
S-albumin median,
(range)
11***
(3.4-31)
3.5
(0-12)
3.1
(0-22)
Men
n, (%)
33
(60)
9
(60)
8
(38)
Women
n, (%)
26
(40)
6
(40)
13
(62)
Median age
years, (range)
9
(3-14)
7
(2-13)
9
(2-13)
Median duration of
symptoms before LP;
weeks, (range)
2.0
(0-8.0)
0.7
(0.1-4.0)
1.7
(0-13)
¤ There were no children in groups 2 and 5.
NB: neuroborreliosis.
n: number of patients.
AI: antibody index.
CSF:cerebrospinal fluid.
Pleocytosis:>5 mononuclear cells/μL CSF.
S: serum.
LP: lumbar puncture.
* significant differences compared with the non-NB group. * p < 0.01, ** p <
0.001, *** p < 0.0001.
Table 3 Clinical features of patients with confirmed
neuroborreliosis, stratified into two groups depending
on the IL-17 level in cerebrospinal fluid.
IL-17 in CSF
<0.80 pg/mL
n = 68
IL-17 in CSF
>0.80 pg/mL
n = 65
Pleocytosis
median number of cells/μL, (range)
138
(8-384)
184*
(10-1650)
CSF-albumin
S-albumin median, (range)
14.3
(3.4-59.6)
18.1
(3.8-76.0)
Median age
years, (range)
48
(3-87)
14
(3-77)
Median duration of
symptoms before LP
weeks, (range)
2.0
(0.1-25.0)
3.0
(0-32.0)
Cranial nerve palsy
n, (%)
37
(54.4)
33
(50.8)
Muscle and joint pain
n, (%)
32
(47.1)
27
(41.5)
Radiculitis
n, (%)
30
(44.1)
23
(35.4)
Neck pain
n, (%)
22
(32.4)
25
(38.5)
Headache
n, (%)
26
(28.2)
29
(44.6)
Fatigue
n, (%)
17
(25.0)
31*
(47.7)
Parestesias
n, (%)
12
(17.6)
11
(16.9)
Fever >38°C
n, (%)
10
(14.7)
16
(24.6)
Vertigo
n, (%)
4
(5.9)
6
(9.2)
Concentration difficulties
n, (%)
2
(2.9)
2
(3.1)
CSF: cerebrospinal fluid.
LP: lumbar puncture.
S: serum.
n: number of patients.
°C: degrees Celsius.
* significant differences between the two groups. * p < 0.01, ** p < 0.001, ***
p < 0.0001.
Patients could have one or several symptoms.
Henningsson et al. Journal of Neuroinflammation 2011, 8:36
http://www.jneuroinflammation.com/content/8/1/36
Page 7 of 11
a)
Patient groups
C
XC
L8
 in
 s
er
um
 (l
og
1
0
pg
/m
L)
1 3 4
1
10
100
1000
10000 p<0.0001p<0.0001
b)
Patient groups
C
XC
L8
 in
 C
SF
 (l
og
1
0
pg
/m
L)
1 3 4
1
10
100
1000
10000
p<0.0001
p<0.0001
c)
Patient groups
IL
-1
7 
in
 s
er
um
 (l
og
1
0
pg
/m
L)
1 3 4
0.1
1
10
100
1000
10000 p<0.01p<0.01
d)
Patient groups
IL
-1
7 
in
 C
SF
 (l
og
1
0
pg
/m
L)
1 3 4
0.1
1
10
100
p<0.0001
p<0.0001
e)
Patient groups
C
XC
L1
0 
in
 s
er
um
 (l
og
1
0
pg
/m
L)
1 3 4
10
100
1000
10000
f)
Patient groups
C
XC
L1
0 
in
 C
SF
 (l
og
1
0
pg
/m
L)
1 3 4
10
100
1000
10000
100000
1000000
p<0.0001
p<0.0001
g)
Patient groups
C
C
L2
2 
in
 s
er
um
 (l
og
10
pg
/m
L)
1 3 4
100
1000
10000
100000
h)
Patient groups
C
C
L2
2 
in
 C
SF
 (l
og
1
0
pg
/m
L)
1 3 4
1
10
100
1000 p<0.0001 p=0.001
p<0.0001
Figure 2 Cytokine/chemokine levels (pg/mL) in serum and in cerebrospinal fluid (CSF) in patients <15 years of age. Group 1: Confirmed
neuroborreliosis (NB), patients with elevated Borrelia-specific antibody index or Borrelia-specific antibodies in CSF and pleocytosis. Group 3:
Possible early NB, patients with CSF pleocytosis but no detectable Borrelia-specific antibodies in CSF. Group 4: Non-NB, patients without
pleocytosis and no detectable Borrelia-specific antibodies in CSF. (There were no children in groups 2 and 5). Bars represent the median
cytokine/chemokine level in each group.
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since neither the serum levels of IL-17 nor the CSF-
albumin/S-albumin ratios correlated with the CSF levels
of IL-17.
As to findings in serum, the patients with confirmed
NB showed significantly higher levels of CXCL10 as
compared to groups 2 and 4, possibly reflecting that the
strong Th1 response in the CNS also is associated with
a systemic response. However, the orthopaedic control
patients also displayed elevated CXCL10 levels in serum.
It could be speculated that this finding might be related
to age [46]. Surprisingly, children with possible early NB
(group 3) showed significantly lower levels of CXCL8 in
serum, and this finding persisted in the comparison
across groups 1, 3 and 4 when all adult patients were
excluded. Otherwise, no significant differences were
found across groups for cytokine/chemokine levels in
serum, confirming that the inflammatory process is
mainly restricted to the CNS compartment [13].
We also attempted to find correlations between cyto-
kine/chemokine levels and clinical parameters including
the course of disease. However, no such correlations
were found, which implies that cytokine/chemokine
levels do not seem to be useful clinical predictors of the
disease course. However, we can not exclude that such
correlations would have been revealed if a standardized
follow-up protocol had been applied in a prospective
manner.
One limitation to this study is the difficulty to find an
appropriate control group. The use of completely
healthy control patients with no symptoms and no other
disorders would of course be desirable, but it is gener-
ally very difficult to obtain CSF samples from healthy
volunteers. Importantly, we included a control group
(group 5) where CSF was not obtained due to suspicion
of NB. We also believe that our non-NB group (group
4) is quite useful, since the patients have neither signs
of ongoing Borrelia infection, nor any signs of CNS
inflammation, and it is our opinion that the inflamma-
tion in NB is mainly restricted to the CNS compart-
ment. Furthermore, there were no significant differences
found between the non-NB group and the control group
(group 5), except for higher serum levels of CXCL10 in
the control group as discussed above. Another possible
limitation to this study is the difference in age between
patients in group 3 (children with possible early NB)
and patients in the other groups. However, when com-
paring group 3 to the children in groups 1 and 4, we
obtained the same results as when including the adults
in the analysis.
The samples had been stored at -20°C and thawed
once before. However, chemokines are fairly robust, and
concentrations were measurable using the methods
described here. Furthermore, all samples had been
handled and stored under the same conditions. It is also
worth noting that we here measured the concentrations
of circulating cytokine/chemokines, and the results
could be different at a cellular level. However, CXCL10
and CCL22 seem to roughly reflect previous data on
Th1 and Th2 [9-15].
Conclusions
Our results support the notion that a Th1-type immune
response dominates in the CNS in early NB, and is then
followed by a Th2-type immune response. We suggest
that chemokines are suitable and feasible markers for
measuring of Th1/Th2 responses. We also show that IL-
17 levels are increased in CSF in a substantial propor-
tion of NB cases, suggesting a role for Th17 in NB.
However, the precise role of Th17 in NB pathogenesis
and clinical course remains to be evaluated.
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